A Fluorinated BODIPY-Based Zirconium Metal–Organic Framework for In Vivo Enhanced Photodynamic Therapy
Authors:
Top Cited Papers
Open Access
- 4 January 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (2) , 1644-1656
Abstract
Photodynamic therapy (PDT), an emergent noninvasive cancer treatment, is largely dependent on the presence of efficient photosensitizers (PSs) and a sufficient oxygen supply. However, the therapeutic efficacy of PSs is greatly compromised by poor solubility, aggregation tendency, and oxygen depletion within solid tumors during PDT in hypoxic microenvironments. Despite the potential of PS-based metal-organic frameworks (MOFs), addressing hypoxia remains challenging. Boron dipyrromethene (BODIPY) chromophores, with excellent photostability, have exhibited great potential in PDT and bioimaging. However, their practical application suffers from limited chemical stability under harsh MOF synthesis conditions. Herein, we report the synthesis of the first example of a Zr-based MOF, namely, 69-L2, exclusively constructed from the BODIPY-derived ligands via a single-crystal to single-crystal post-synthetic exchange, where a direct solvothermal method is not applicable. To increase the PDT performance in hypoxia, we modify 69-L2 with fluorinated phosphate-functionalized methoxy poly(ethylene glycol). The resulting 69-L2@F is an oxygen carrier, enabling tumor oxygenation and simultaneously acting as a PS for reactive oxygen species (ROS) generation under LED irradiation. We demonstrate that 69-L2@F has an enhanced PDT effect in triple-negative breast cancer MDA-MB-231 cells under both normoxia and hypoxia. Following positive results, we evaluated the in vivo activity of 69-L2@F with a hydrogel, enabling local therapy in a triple-negative breast cancer mice model and achieving exceptional antitumor efficacy in only 2 days. We envision BODIPY-based Zr-MOFs to provide a solution for hypoxia relief and maximize efficacy during in vivo PDT, offering new insights into the design of promising MOF-based PSs for hypoxic tumors.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/P030467/1, EP/S009000/1)
- Fundação para a Ciência e a Tecnologia (2020.06638.BD)
- H2020 European Research Council (726380, 848325)
This publication has 66 references indexed in Scilit:
- Adipose tissue and adipocytes support tumorigenesis and metastasisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Two photoluminescent metal–organic frameworks based on a BODIPY-derived bipyridine ligandCrystEngComm, 2013
- Triplet photosensitizers: from molecular design to applicationsChemical Society Reviews, 2013
- BODIPY dyes in photodynamic therapyChemical Society Reviews, 2012
- Light-Harvesting Metal–Organic Frameworks (MOFs): Efficient Strut-to-Strut Energy Transfer in Bodipy and Porphyrin-Based MOFsJournal of the American Chemical Society, 2011
- Porous Interpenetrated Zirconium–Organic Frameworks (PIZOFs): A Chemically Versatile Family of Metal–Organic FrameworksChemistry – A European Journal, 2011
- Singlet oxygen: there is indeed something new under the sunChemical Society Reviews, 2010
- Hypoxia, HIF1 and glucose metabolism in the solid tumourNature Reviews Cancer, 2008
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Single-crystal structure validation with the programPLATONJournal of Applied Crystallography, 2003